Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer

Ahmadzadeh, 2009, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 114, 1537, 10.1182/blood-2008-12-195792 Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, 8, 793, 10.1038/nm730 Iwai, 2002, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc Natl Acad Sci U S A, 99, 12293, 10.1073/pnas.192461099 Reiss, 2014, Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy, Immunotherapy, 6, 459, 10.2217/imt.14.9 Francisco, 2009, PD-L1 regulates the development, maintenance, and function of induced regulatory T cells, J Exp Med, 206, 3015, 10.1084/jem.20090847 Zitvogel, 2011, Immune parameters affecting the efficacy of chemotherapeutic regimens, Nat Rev Clin Oncol, 8, 151, 10.1038/nrclinonc.2010.223 Galon, 2013, The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures, Immunity, 39, 11, 10.1016/j.immuni.2013.07.008 Denkert, 2010, Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J Clin Oncol, 28, 105, 10.1200/JCO.2009.23.7370 Ali, 2014, Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients, Ann Oncol, 25, 1536, 10.1093/annonc/mdu191 Loi, 2013, Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98, J Clin Oncol, 31, 860, 10.1200/JCO.2011.41.0902 Perez, 2016, Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer, JAMA Oncol, 2, 56, 10.1001/jamaoncol.2015.3239 Loi, 2014, Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial, Ann Oncol, 25, 1544, 10.1093/annonc/mdu112 Ono, 2012, Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer, Breast Cancer Res Treat, 132, 793, 10.1007/s10549-011-1554-7 Yamaguchi, 2012, Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer, Hum Pathol, 43, 1688, 10.1016/j.humpath.2011.12.013 Mahmoud, 2011, Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer, J Clin Oncol, 29, 1949, 10.1200/JCO.2010.30.5037 Lee, 2013, Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients, J Breast Cancer, 16, 32, 10.4048/jbc.2013.16.1.32 Ghebeh, 2006, The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors, Neoplasia, 8, 190, 10.1593/neo.05733 Muenst, 2013, The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer, Breast Cancer Res Treat, 139, 667, 10.1007/s10549-013-2581-3 Nanda, 2016, Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study, J Clin Oncol, 34, 2460, 10.1200/JCO.2015.64.8931 Wimberly, 2015, PD-L1 expression correlates with tumor-Infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer, Cancer Immunol Res, 3, 326, 10.1158/2326-6066.CIR-14-0133 Sabatier, 2015, Prognostic and predictive value of PDL1 expression in breast cancer, Oncotarget, 6, 5449, 10.18632/oncotarget.3216 Elston, 1991, Pathological prognostic factors in breast cancer. I. the value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, 19, 403, 10.1111/j.1365-2559.1991.tb00229.x Turner, 2006, Basal-like breast cancer and the BRCA1 phenotype, Oncogene, 25, 5846, 10.1038/sj.onc.1209876 Allred, 1998, Prognostic and predictive factors in breast Cancer by immunohistochemical analysis, Mod Pathol, 11, 155 Wolff, 2007, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol, 25, 118, 10.1200/JCO.2006.09.2775 Muenst, 2014, Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer, Breast Cancer Res Treat, 146, 15, 10.1007/s10549-014-2988-5 Guo, 2016, Prognostic and clinicopathological value of programmed death ligand-1 in breast cancer: a meta-analysis, PLoS One, 11 Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824 Taube, 2012, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med, 4, 127ra37, 10.1126/scitranslmed.3003689 Sznol, 2013, Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer, Clin Cancer Res, 19, 1021, 10.1158/1078-0432.CCR-12-2063 Teng, 2015, Classifying cancers based on T-cell infiltration and PD-L1, Cancer Res, 75, 2139, 10.1158/0008-5472.CAN-15-0255 Schalper, 2014, In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas, Clin Cancer Res, 20, 2773, 10.1158/1078-0432.CCR-13-2702 Gatalica, 2014, Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type, Cancer Epidemiol Biomarkers Prev, 23, 2965, 10.1158/1055-9965.EPI-14-0654